Marvin L. White
CIK: 0001493324
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Aug 6, 2026APVO
Aptevo Therapeutics Inc.
Tax Payment(F)Direct406 shares at avg. $4.07$2K - Aug 6, 2026APVO
Aptevo Therapeutics Inc.
Exercise(M)Direct1.7K shares- - Jul 17, 2026APVO
Aptevo Therapeutics Inc.
Exercise(M)Direct1 shares- - Apr 30, 2026EBS
Emergent BioSolutions Inc.
Award(A)Direct25.3K shares- - Aug 6, 2025APVO
Aptevo Therapeutics Inc.
Award(A)DirectRestricted Stock Unit
30K shares- - Jul 17, 2025APVO
Aptevo Therapeutics Inc.
Exercise(M)Direct10 shares- - Apr 30, 2025EBS
Emergent BioSolutions Inc.
Award(A)Direct34.4K shares- - Mar 3, 2025APVO
Aptevo Therapeutics Inc.
Exercise(M)Direct6 shares- - Mar 2, 2025APVO
Aptevo Therapeutics Inc.
Exercise(M)Direct8 shares- - Nov 11, 2024EBS
Emergent BioSolutions Inc.
Sale(S)Direct14.3K shares at avg. $11.97$171K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 6, 2026 |  APVO Aptevo Therapeutics Inc. | Tax Payment(F) | 406 | $4.07 | $1,652 | Direct |
| Aug 6, 2026 | APVO Aptevo Therapeutics Inc. | Exercise(M) | 1,666 | - | $0 | Direct |
| Jul 17, 2026 | APVO Aptevo Therapeutics Inc. | Exercise(M) | 1 | - | $0 | Direct |
| Apr 30, 2026 |  EBS Emergent BioSolutions Inc. | Award(A) | 25,344 | - | $0 | Direct |
| Aug 6, 2025 | APVO Aptevo Therapeutics Inc. | Award(A) Restricted Stock Unit | 30,000 | - | - | Direct |
| Jul 17, 2025 | APVO Aptevo Therapeutics Inc. | Exercise(M) | 10 | - | - | Direct |
| Apr 30, 2025 | EBS Emergent BioSolutions Inc. | Award(A) | 34,403 | - | - | Direct |
| Mar 3, 2025 | APVO Aptevo Therapeutics Inc. | Exercise(M) | 6 | - | - | Direct |
| Mar 2, 2025 | APVO Aptevo Therapeutics Inc. | Exercise(M) | 8 | - | - | Direct |
| Nov 11, 2024 | EBS Emergent BioSolutions Inc. | Sale(S) | 14,287 | $11.97 | $171,015 | Direct |
1-10 of 10 transactions
About White Marvin L
White Marvin L (SEC CIK 0001493324) files insider reports with the SEC as Executive Chair of Aptevo Therapeutics Inc. (APVO) and Director of Emergent BioSolutions Inc. (EBS).
Signal8 holds 7 ownership filings by White Marvin L, all Form 4s, filed between Nov 13, 2024 and Aug 10, 2026. Those filings report 10 transactions, from Nov 11, 2024 to Aug 6, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on White Marvin L's filings is in SEATTLE, WA.
Recent filings by White Marvin L
- Aug 6, 2026: Tax withholding of APVO shares (Form 4, code F).
- Aug 6, 2026: Option exercise of APVO shares (Form 4, code M).
- Jul 17, 2026: Option exercise of APVO shares (Form 4, code M).
- Apr 30, 2026: Grant or award of EBS shares (Form 4, code A).
- Aug 6, 2025: Grant or award of APVO derivative securities (Form 4, code A).
Other insiders filing for Aptevo Therapeutics Inc. (APVO)
- Harsanyi Zsolt, Director
- Lamothe Jeffrey G., President and CEO
- Taylor Daphne, SVP, CFO
- Kwon SoYoung, SVP, GC, BD & Corp Affairs
- Huebner Dirk, SVP, CMO
- Grant Grady III, Director